

[Dacarbazine](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01AX04](#)

EMLc

Indication

Hodgkin lymphoma ICD11 code: [2C10.Z](#)

INN

Dacarbazine

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 100 mg in vial powder for injection ; 200 mg in vial powder for injection

EML status history

First added in 1989 ([TRS 796](#))

Changed in 2002 ([TRS 914](#))

Changed in 2007 ([TRS 950](#))

Changed in 2011 ([TRS 965](#))

Changed in 2015 ([TRS 994](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Dacarbazine](#)

DrugBank

[Dacarbazine](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional strength formulation of dacarbazine powder for injection (200 mg in vial) to the EML and EMLc.